Comments
Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India, has announced the discovery and initiation of investigational new drug enabling studies for a novel clinical development candidate, GBR 1342, targeting oncology indications. The molecule is the second clinical development candidate targeting cancer. The company said the antibody is a well established target for multiple myeloma, a cancer caused by malignant plasma cells, and is potentially also a target for other hematopoietic malignancies.
Michael Buschle, Chief Scientific Officer and President, Biologics, Glenmark Pharmaceuticals, said with the earlier (1302) project, “we learned how to efficiently engineer and manufacture this novel type of antibody and we are now applying those lessons to several other targets”. Glenmark has three monoclonal antibodies in the novel biologics entity pipeline undergoing active clinical development.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.